This post was updated in 2020 and is part of our SCOPE stem cells not lost in translation project. You can learn more about the project and read the other 34 languages on that page.
What are stem cells?
The human body contains hundreds of different types of cells that are important for our daily health. These cells are responsible for keeping our bodies running each day such as making our hearts beat, brains think, kidneys clean our blood, replace our skin cells as they shed off, and so on. The unique job of stem cells is to make all these other types of cells. They are the suppliers of new cells. When stem cells divide they can make more of themselves or more of other types of cells. For example, stem cells in skin can make more of themselves or they can make differentiated cells of the skin that have specific jobs of their own such as making the melanin pigment.
Why are stem cells important for your health?
When we get injured or sick, our cells also are injured or killed. When this happens, stem cells become active. Stem cells have the job of fixing our injured tissues and of replacing other cells when they routinely die. In this way our stem cells keep us healthy and prevent us from prematurely aging. Stem cells are like our own army of microscopic doctors.
What are the different kinds of stem cells?
Stem cells come in many different forms. Scientists think that every organ of our body has its own specific type of stem cells. For example, our blood is made from blood (also known as hematopoietic) stem cells. However, stem cells are also present from the earliest stages of human development, and when scientists grow these, they are called embryonic stem cells. The reason scientists are excited about embryonic stem cells is that the natural job of embryonic stem cells is to build every organ and tissue in our bodies during human development. What this means is that embryonic stem cells, unlike adult stem cells, can be coaxed into potentially forming almost any other of the hundreds of types of human cells. For example, while a blood stem cell can only make blood, an embryonic stem cell can make blood, bone, skin, brain, and so on. In addition, embryonic stem cells are programmed by nature to build tissues and even organs, while adult stem cells are not. What this means is that embryonic stem cells have a greater natural capacity to fix diseased organs. Embryonic stem cells are made from leftover embryos from fertility treatments that are only a few days old, that were made in a dish in a laboratory, and that would otherwise be thrown away.
What are iPS or induced pluripotent stem cells?
Scientists and doctors are excited about this new type of stem cell called iPS cells. The reason we are excited is because iPS cells have almost all the same properties as embryonic stem cells, but are not made from an embryo. Thus, there are no ethical concerns with iPS cells. In addition, iPS cells are made from a patients own non-stem cells, meaning that iPS cells could be given back to a patient without risk of immune rejection, an important issue with any stem cell transplant.
What does the future hold and how could stem cells change how your doctor treats you?
Because by nature stem cells have the job of replacing sick or old cells, scientists have conceived the idea of using stem cells as therapies for patients with a wide variety of medical conditions. The idea here is that by giving a sick patient stem cells or differentiated cells made from stem cells, we can make use of the stem cells natural ability to heal to make the patient healthy again. For example, if a patient has a heart attack, by giving that patient a transplant of stem cells as a therapy our goal is to have the transplanted stem cells repair the damage to the heart. The natural populations of stem cells that we all possess have only a limited capacity to fix injuries to our bodies. Going back to the example of the heart, the hearts own stem cells are just not up to the task of fixing the damage from a heart attack, but a transplant of millions of stem cells would be far more powerful. Therefore by giving patients transplants of stem cells we boost the bodys ability to heal beyond the capabilities of the limited number of naturally occurring stem cells. Some challenges remain to be addressed before stem cell therapies become more common including safety, as stem cells can potentially form tumors, and immune rejection. Even so, stem cells are likely to transform medicine and in perhaps just one or two decades most of us will know someone, perhaps even ourselves, who has had a stem cell transplant. Stem cells hold promise to treat most of the major diseases that people face including cancer, heart disease, Parkinsons Disease, Multiple Sclerosis, Stroke, Huntingtons Disease, spinal cord injury, and many more.
What stem cell treatments are available now and why most doctors recommend that you should only consider those with caution and as a last resort?
Currently, there are few stem cell transplants available that are proven by scientists to be both safe and effective. The best example is bone marrow transplantation. However, many unproven stem cell treatments are being advertised and offered around the world. Often these treatments get a lot of attention in the media, frequently when celebrities such as sports stars get these treatments. Generally, scientists and doctors in the stem cell field caution patients against such treatments because it is unclear whether these treatments actually work and whether they are safe. Patients have died from such treatments. While it is reasonable to consider all options when facing a potentially incurable condition or disease, we recommend that you only consider such treatments as a last resort and only after talking with your personal physician.
By Paul Knoepfler
Note that you may also find this Closer Look at Stem Cells resource page very helpful.
See the rest here:
What are stem cells? A 2020 updated resource - The Niche
- Multifactorial approach is needed to unravel the maturation phases of human neurons derived from induced pluripotent stem cells - Nature.com - January 21st, 2025
- Unlock the Potential of iPSC Differentiation with Creative Biolabs - EIN News - January 17th, 2025
- Automated iPS Cell Production to Start in Japan in April - Nippon.com - January 9th, 2025
- iPSCs: take the survey and win! - RegMedNet - January 9th, 2025
- Automated iPS cell production to start in Japan in April - The Japan Times - January 9th, 2025
- Dysregulation of mTOR signalling is a converging mechanism in lissencephaly - Nature.com - January 1st, 2025
- BrightPath-Cellistic partner for clinical trial advancements of CAR-T cell therapy - Yahoo Finance - December 17th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 15th, 2024
- BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT... - December 13th, 2024
- Induced Pluripotent Stem Cells: Problems and Advantages when Applying ... - December 7th, 2024
- What are Induced Pluripotent Stem Cells? | ISCRM - December 7th, 2024
- Induced pluripotent stem cells, a giant leap for mankind therapeutic ... - December 7th, 2024
- Advantages and disadvantages of induced pluripotent stem cells - December 7th, 2024
- Generation and long-term culture of human cerebellar organoids from pluripotent stem cells - Nature.com - December 3rd, 2024
- Whats the secret to living to 100? Centenarian stem cells could offer clues - Nature.com - December 1st, 2024
- Single-cell RNA sequencing reveals key regulators and differentiation trajectory of iPSC-derived cardiomyocytes - Nature.com - November 26th, 2024
- Cell therapy weekly: GMP certification of iPSC-focused manufacturing facility - RegMedNet - November 25th, 2024
- Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - Pharmaceutical Technology - November 22nd, 2024
- Alloy Therapeutics, Takeda Partner on Revolutionary iPSC Cell Therapy Platform | TAK Stock News - StockTitan - November 22nd, 2024
- A remarkable study was released this week. It is a Japanese researcher's paper that restored vision - - November 18th, 2024
- World's first stem cell treatment restores vision, offers new hope to the blind - India Today - November 12th, 2024
- The Breakthroughs of Vision Restoration - The New Importance of Stem Cells - Yahoo News UK - November 12th, 2024
- Modified stem cell therapy aids motor function in mice with... - Parkinson's News Today - October 30th, 2024
- Team achieves successful reproduction of hematopoietic stem cell developmental process in an in vitro culture system - Phys.org - October 22nd, 2024
- Human Pluripotent Stem Cells (iPSC) Generation, Culture, and ... - October 11th, 2024
- Induced pluripotent stem cell technology: a decade of progress - October 11th, 2024
- Nobel Winner Shinya Yamanaka: Cell Therapy Is Very Promising For Cancer, Parkinsons, More - Forbes - October 10th, 2024
- Human Induced Pluripotent Stem Cells : Clinical Significance and ... - October 6th, 2024
- Induced pluripotent stem cells: Mechanisms, achievements and ... - October 6th, 2024
- Induced pluripotent stem cells | UCLA BSCRC - October 6th, 2024
- Unlocking new regenerative pathways in iPS cellderived epicardium for cardiac repair - Medical Xpress - October 4th, 2024
- Artificial heart made of iPS cells unveiled to press, to be displayed at 2025 Osaka expo - The Mainichi - The Mainichi - October 2nd, 2024
- Trial planned on sparing diabetes patients from insulin injections - - September 30th, 2024
- Leveraging the power of iPS cell technology to study myeloid neoplasm - Medical Xpress - September 10th, 2024
- Kyoto University Hospital seeks to treat Type 1 diabetes using iPS cells - The Japan Times - September 4th, 2024
- Kyoto Hospital to Test Using Ips Cells to Treat Diabetes; Seeks to Reduce Burden of Multiple Daily Insulin Injections - The Japan News - September 4th, 2024
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants - August 24th, 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine - August 24th, 2024
- Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - August 24th, 2024
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 - August 24th, 2024
- Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow - August 24th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 24th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - August 24th, 2024
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies... - August 24th, 2024
- Novel insights from Human Induced Pluripotent Stem Cells on Origins and Roles of Fibro/Adipogenic Progenitors as Heterotopic Ossification Precursors -... - August 22nd, 2024
- Optimization of a human induced pluripotent stem cell-derived sensory neuron model for the in vitro evaluation of taxane-induced neurotoxicity -... - August 18th, 2024
- Culture Techniques for Drug Discovery and Therapeutics - Technology Networks - August 16th, 2024
- iPSC culture techniques for drug discovery and therapeutics - Labmate Online - August 12th, 2024
- Neuroprotective and anti-inflammatory properties of proteins secreted by glial progenitor cells derived from human iPSCs - Frontiers - August 6th, 2024
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 31st, 2024
- Purification technologies for induced pluripotent stem cell therapies - Nature.com - July 28th, 2024
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results - July 26th, 2024
- Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research - July 26th, 2024
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - July 26th, 2024
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 - July 26th, 2024
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 - July 26th, 2024
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study - July 26th, 2024
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - July 26th, 2024
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 - July 26th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 - July 26th, 2024
- Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia - July 26th, 2024
- scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic... - July 26th, 2024
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 - July 26th, 2024
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - July 26th, 2024
- Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - July 26th, 2024
- Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment... - July 26th, 2024
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health... - July 26th, 2024
- Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 - July 26th, 2024
- 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support - July 26th, 2024
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - July 26th, 2024
- ISSCR 2024: iPS cell line panels can be isogenic and diverse - BioWorld Online - July 16th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - PR Newswire - July 10th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - The Manila Times - July 10th, 2024
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment - July 5th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
- Monthly information on share capital and company voting rights - July 5th, 2024
Recent Comments